Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
Recruiting · NCT05649098 · Registry updated 2026-05-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Infant, Newborn, Diseases, Pathological Conditions, Signs and Symptoms, Pruritus, Signs and Symptoms, Skin Abnormalities, Skin Manifestations, Skin and Connective Tissue Diseases, epidermolysis bullosa, hereditary disease, hereditary skin disorder, ichthyosis, keratosis, skin disorder, vesiculobullous skin disease | Recruiting | Early phase 1 | 2026-05-01 | NCT05649098 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Northwestern University | 381 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | United States | 144 |